Effect of Intranasal Dexmedetomidine on the Incidence of Emergence Agitation in Children Undergoing Strabismus Surgery
Effect of Two Different Doses of Intranasal Dexmedetomidine on the Incidence of Emergence Agitation in Children Undergoing Strabismus Surgery , A Randomized Clinical Trial
Alexandria University
120 participants
Mar 1, 2026
INTERVENTIONAL
Conditions
Summary
Dexmedetomidine is a selective a-2 adrenergic agonist that provides sedative and analgesic effects. Intranasal dexmedetomidine has a slower and gradual onset compared to intravenous injection , with low incidence of nasal discomfort. Dexmedetomidine was tested at various doses and modes of administration, as well as different types of surgery and co-anesthetic drugs, as a single injection or continuous infusion. The authors have not agreed on the ideal clinical dose. The hypothesis is that intranasal dexmedetomidine 3mcg /kg will decrease the incidence of emergence agitation after strabismus surgery than dexmedetomidine 2 mcg/kg
Eligibility
Inclusion Criteria2
- Age: 3-6 years, both sexes
- ASA physical status class I , II.
Exclusion Criteria5
- history of neurological and psychiatric disease
- body mass index > 20 kg m-2
- allergy to dexmedetomidine
- patients on medical treatment which has any sedative effect
- mentally retarded children
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
patients will receive 3 mcg/kg intranasal dexmedetomidine 45minutes before surgery
patients will receive 2 mcg/kg intranasal dexmedetomidine 45minutes before surgery
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07523438